三生國健(688336.SH):2024年淨利潤7.05億元,同比增長139.15%
格隆匯3月25日丨三生國健(688336.SH)公佈2024年年度報告,報告期實現營業收入11.94億元,同比增長17.70%;歸屬於上市公司股東的淨利潤7.05億元,同比增長139.15%;基本每股收益1.14元。公司擬向全體股東每10股派發現金紅利人民幣0.90元(含稅)。
歸屬於上市公司股東的淨利潤相比上年同期大幅增長,主要原因系①銷售收入穩步上漲;②本公司按照持股比例計算享有聯營企業Numab一次性特別股息分配4.11億元,計入2024年度投資收益,導致2024年度利潤大幅增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.